23.02.2010 • Product

Low Cost Parallel Synthesizer

Photo

The new DrySyn Parallel Synthesizer allows the chemist to heat and stir up to 12 small-scale reactions in parallel using any standard hotplate stirrer. At around £200 this provides a convenient, low cost solution for chemists wishing to conduct simple synthetic reactions with temperature control and magnetic stirring, but without the complications of reflux or inerting. It is ideal for producing small, focused libraries of compounds.
The DrySyn Parallel Synthesizer accommodates a range of standard reaction tubes and vials, of different diameters. It can also be upgraded to a parallel reaction station using standard round-bottom flasks, by using the appropriate DrySyn Multi inserts. In this configuration, facilities like reflux and gas control can be added, it also can be upgraded further with directly driven stirring with the Asynt Vortex stirrer system.
DrySyn systems can heat reactions to over 300°C and are available for single or multiple reaction vessels with volumes from 1ml to 5000ml. Compatible with any standard hotplate stirrer, they combine a small footprint with excellent reaction visibility. According to Asynt Managing Director Martyn Fordham, over 25,000 DrySyn laboratory heating and cooling blocks have now been supplied world wide.

Company

Asynt Ltd.

Unit 29, Hall Barn Road
CB7 5RJ Isleham, Cambridgeshire

Company contact







Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read